Mu Likun, Mu Lina, Ye Jing, Cheng Lifeng
Department of Neurosurgery, Shengli Oilfield Center Hospital, Dongying, Shandong, 257099, China.
Department of Neurosurgery, Changle County Hospital of Traditional Chinese Medicine, Weifang, Shandong, 262499, China.
Neurol Sci. 2025 May;46(5):2203-2208. doi: 10.1007/s10072-025-07989-z. Epub 2025 Jan 6.
This study aimed to evaluate the clinical efficacy and safety of minimally invasive hematoma evacuation for the treatment of traumatic intracranial hematoma (TIH).
Ninety patients diagnosed with traumatic intracerebral hematoma at Shengli Oilfield Central Hospital from August 2019 to September 2023 were selected as the study subjects. The patients were divided into the craniotomy group (C group, n = 45) and the minimally invasive hematoma evacuation group (MIHE group, n = 45). Patients in group MIHE were treated with minimally invasive hematoma evacuation according to the amount and location of the TIH. The patients' baseline characteristics, the good prognosis rate, the neurological function index, the hospitalization cost and the incidence rate of complications were compared between the two groups. The status of the patients after surgical treatment was determined according to the Glasgow Outcome Scale.
The good prognosis rate in the MIHE group (39, 86.67%) was significantly higher than that in the C group (31, 68.89%) (p < 0.05). National Institute of Health stroke scale (NIHSS) scores were significantly lower in the MIHE group than in the C group (p < 0.05). The hospitalization cost and hospitalization time in the MIHE group were significantly lower than those in the C group (p < 0.05). The total incidence rate of complications in the MIHE group (20, 44.44%) was significantly lower than that in the C group (11, 24.44%) (p < 0.05).
For some patients, minimally invasive hematoma evacuation is a more effective treatment strategy than craniotomy for patients with TIH. It has the advantages of less surgical trauma, complete clearance of hematoma and fewer postoperative complications, which is conducive to the recovery of neurological function and postoperative rehabilitation.
本研究旨在评估微创血肿清除术治疗创伤性颅内血肿（TIH）的临床疗效和安全性。
选取2019年8月至2023年9月在胜利油田中心医院诊断为创伤性脑内血肿的90例患者作为研究对象。将患者分为开颅手术组（C组，n = 45）和微创血肿清除术组（MIHE组，n = 45）。MIHE组患者根据TIH的出血量和位置进行微创血肿清除术治疗。比较两组患者的基线特征、良好预后率、神经功能指标、住院费用和并发症发生率。根据格拉斯哥预后量表确定手术治疗后患者的状态。
MIHE组的良好预后率（39例，86.67%）显著高于C组（31例，68.89%）（p < 0.05）。MIHE组的美国国立卫生研究院卒中量表（NIHSS）评分显著低于C组（p < 0.05）。MIHE组的住院费用和住院时间显著低于C组（p < 0.05）。MIHE组并发症总发生率（20例，44.44%）显著低于C组（11例，24.44%）（p < 0.05）。
对于部分患者，微创血肿清除术治疗TIH比开颅手术更有效。它具有手术创伤小、血肿清除彻底、术后并发症少等优点，有利于神经功能恢复和术后康复。
